For the quarter ended March 2025, Edwards Lifesciences (EW) reported revenue of $1.41 billion, down 11.6% over the same period last year. EPS came in at $0.64, compared to $0.66 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.4 billion, representing a surprise of +0.71%. The company delivered an EPS surprise of +6.67%, with the consensus EPS estimate being $0.60. Here is how Edwards Lifesciences performed in the just reported quarter in terms of the metrics most ...

财务表现 - 公司报告季度收入为2.6287亿美元，同比增长6.3% [1] - 每股收益(EPS)为3.11美元，去年同期为2.56美元 [1] - 收入超出Zacks共识预期2.24%，EPS超出预期14.76% [1] 市场反应 - 公司股价过去一个月下跌6.6%，同期标普500指数下跌8.9% [3] - 目前Zacks评级为3级(持有)，表明近期表现可能与大盘一致 [3] 关键运营指标 - 净息差为6.5%，低于分析师平均预期的6.7% [4] - 总生息资产平均余额为77.6亿美元，高于分析师预期的70亿美元 [4] - 非利息收入为1.3852亿美元，略高于分析师预期的1.3771亿美元 [4] - 净利息收入为1.2434亿美元，高于分析师预期的1.1525亿美元 [4] 投资者关注点 - 投资者密切关注同比变化和华尔街预期的比较以决定投资策略 [2] - 关键指标更能反映公司实际运营状况，对预测股价表现有重要作用 [2]